Drugs / human interferon beta 1a
human interferon beta 1a
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT00618527 | Aug 2006 → May 2012 | multiple sclerosis | Aaron Boster | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT00428584 | Dec 2006 → Nov 2007 | relapsing-remitting multiple sclerosis | EMD Serono | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-06-18 | Merck KGaA, Darmstadt, Germany | Results Data Provide Further Insight Into the Consistent Efficacy Benefits of Mavenclad in Relapsing MS prnewswire.com ↗
Furthermore, additional post hoc data from clinical studies of patients treated with Rebif (subcutaneous interferon beta-1a) showed that the MAGNIMS score at Year 1 reliably predicted long-term clinical disease activity (CDA)-free status and disability progression. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-06-18 | Merck KGaA, Darmstadt, Germany | Data Provide Further Insight Into the Consistent Efficacy Benefits of Mavenclad in Relapsing MS prnewswire.com ↗ |
| 2018-06-14 | Merck KGaA, Darmstadt, Germany | Merck to Present Data on Mavenclad® and Rebif® in Relapsing Forms of Multiple Sclerosis at EAN prnewswire.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | human interferon beta-1a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00428584 ↗ |
| Known as | IFNβ-1a | “Eligible patients aged 18-60 years were randomized to receive either IFNβ-1a, titrated to 44 μg sc three times weekly (tiw) (n = 65), or IFNβ-1b, titrated to 250 μg sc every...” PMID 23216674 ↗ Dec 2012 |
| Known as | rebif | “New Formulation of rebif - human interferon beta-1a” NCT00428584 ↗ |
| Route | Subcutaneous | “New Formulation of rebif- 44 mcg, SC (sub-cutaneous) thrice weekly (tiw) injection.” NCT00428584 ↗ |